Key result
HELP-apheresis significantly increased mean erythrocyte velocity during the first procedure (p=0.0001) and improved cutaneous microcirculation over 12 months of weekly treatment.
Why the study?
Evidence suggests HELP-apheresis improves microcirculation through endothelial-dependent vasodilatation and hemorheological effects, but its long-term impact in hyperlipidemic heart transplant patients with cardiac allograft vasculopathy required investigation.
Does HELP-apheresis improve cutaneous microcirculation in hyperlipidemic cardiac transplant recipients with cardiac allograft vasculopathy?
Cohort (n=8)
Does HELP-apheresis improve cutaneous microcirculation in hyperlipidemic cardiac transplant recipients with cardiac allograft vasculopathy?
p-value: p=0.0001
HELP-apheresis significantly improves cutaneous microcirculation and capillary perfusion in hyperlipidemic heart transplant recipients with cardiac allograft vasculopathy.
Should not change practice in cardiac allograft vasculopathy; leaves open microcirculatory effects of HELP-apheresis.
Hyperlipidemic heart transplant patients who develop cardiac allograft vasculopathy (CAV) benefit from HELP-apheresis (Heparin-induced Extracorporeal LDL Precipitation) which enables drastic lowering of plasma low-density lipoprotein, lipoprotein (a), and fibrinogen. There is evidence that HELP-apheresis also improves microcirculation by an immediate improvement of impaired endothelial-dependent vasodilatation and additive hemorheological effects.Therefore, cutaneous microcirculation was examined before, during, and after the first HELP-apheresis in eight hyperlipidemic cardiac transplant recipients with CAV. To study the long-term effect the intravital microscopy was repeated after three and 12 months of weekly apheresis treatment.In CAV patients the baseline mean erythrocyte velocity was pathologically reduced with 0.13±0.07 mm/s. During the first HELP-apheresis the erythrocyte velocity increased significantly (p = 0.0001) and remained increased until the end of the HELP procedure (p < 0.05). After three months of weekly apheresis treatment a decrease of temporary flow stops in the capillaries with a progressive homogenization (concordance) of the cutaneous microcirculation was observed. After one year of weekly treatment a markedly increase in mean erythrocyte velocity under resting conditions occurred. In addition, a reactive post-ischemic hyperemia could be established for the first time.Even the first single HELP-apheresis resulted in a significant improvement of the cutaneous microcirculation. The long-term treatment of these patients resulted in a marked improvement of the cutaneous microcirculation with the tendency to a normalization of the regulation of the capillary perfusion.
No takes yet. Share an insight, caveat, or question.
Park et al. (2019) conducted a cohort in Cardiac allograft vasculopathy and concomitant hypercholesterolemia (n=8). HELP-apheresis (Heparin-induced Extracorporeal LDL Precipitation) was evaluated on Cutaneous microcirculation (mean erythrocyte velocity) (p=0.0001). HELP-apheresis significantly increased mean erythrocyte velocity during the first procedure (p=0.0001) and improved cutaneous microcirculation over 12 months of weekly treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: